Table 2 Description of 547 lung cancer patients, Silkeborg Regional Hospital 2013–2018, and comparison of distributions in two periods 2013-2015 (247) and 2016-2018 (300)
2013–2018 (547) | 2013–2015 (247) | 2016–2018 (300) | ||||
|---|---|---|---|---|---|---|
N | % | N | % | N | % | |
Outcome | ||||||
Clinical TNM stage | ||||||
IA | 119 | 21.8 | 34 | 13.8 | 85 | 28.3 |
IB | 42 | 7.7 | 13 | 5.3 | 29 | 9.7 |
II | 42 | 7.7 | 16 | 6.5 | 26 | 8.7 |
IIIA | 54 | 9.9 | 22 | 8.9 | 32 | 10.7 |
IIIB-IIIC | 57 | 10.4 | 27 | 10.9 | 30 | 10.0 |
IV | 208 | 38.0 | 116 | 47.0 | 92 | 30.7 |
NA | 25 | 4.6 | 19 | 7.7 | 6 | 2.0 |
Chi2(6) = 37.1; p < 0.001 | ||||||
Chi2(5) = 27.2; p < 0.001 (ex. NA) | ||||||
Person characteristics and constitution | ||||||
Age at diagnosis | ||||||
Median | Median | |||||
70.7 | 70.8 | |||||
-59 | 66 | 12.1 | 27 | 10.9 | 39 | 13.0 |
60–69 | 192 | 35.1 | 89 | 36.0 | 103 | 34.3 |
70–79 | 216 | 39.5 | 97 | 39.3 | 119 | 39.7 |
≥ 80 | 73 | 13.3 | 34 | 13.8 | 39 | 13.0 |
Chi2(3) = 0.66; p = 0.88 | ||||||
Sex | ||||||
Male | 293 | 53.6 | 132 | 53.4 | 161 | 53.7 |
Female | 254 | 46.4 | 115 | 46.6 | 139 | 46.3 |
Chi2(1) = 0.003; p = 0.96 | ||||||
Charlson comorbidity score | ||||||
0 | 235 | 43.0 | 106 | 42.9 | 129 | 43.0 |
1 | 130 | 23.8 | 60 | 24.3 | 70 | 23.3 |
2 | 83 | 15.2 | 41 | 16.6 | 42 | 14.0 |
≥ 3 | 99 | 18.1 | 40 | 16.2 | 59 | 19.7 |
Chi2(3) = 1.6; p = 0.67 | ||||||
Pack-years | ||||||
≥ 40 | 252 | 46.1 | 116 | 47.0 | 136 | 45.3 |
20–39 | 187 | 34.2 | 78 | 31.6 | 109 | 36.3 |
10–19 | 41 | 7.5 | 18 | 7.3 | 23 | 7.7 |
0–9 | 43 | 7.9 | 24 | 9.7 | 19 | 6.3 |
NA | 24 | 4.4 | 11 | 4.5 | 13 | 4.3 |
Chi2(4) = 3.0; p = 0.56 | ||||||
Chi2(3) = 3.0; p = 0.40 (ex. NA) | ||||||
Morphology | ||||||
Small cell carcinoma | 71 | 13.0 | 40 | 16.2 | 31 | 10.3 |
Adenocarcinoma | 269 | 49.2 | 110 | 44.5 | 159 | 53.0 |
Squamous cell carcinoma | 96 | 17.6 | 47 | 19.0 | 49 | 16.3 |
NSCLC unspecified | 67 | 12.2 | 33 | 13.4 | 34 | 11.3 |
Other and NA | 44 | 8.0 | 17 | 6.9 | 27 | 9.0 |
Chi2(4) = 7.3; p = 0.12 | ||||||
Referral | ||||||
Initiation of referral | ||||||
General practice | 310 | 56.7 | 143 | 57.9 | 167 | 55.7 |
Hospital | 237 | 43.3 | 104 | 42.1 | 133 | 44.3 |
Chi2(1) = 0.27; p = 0.60 | ||||||
Red flag symptoms (PPV, %)a | ||||||
0.0 | 169 | 30.9 | 70 | 28.3 | 99 | 33.0 |
0.1–0.9 | 247 | 45.2 | 109 | 44.1 | 138 | 46.0 |
≥ 1 | 131 | 23.9 | 68 | 27.5 | 63 | 21.0 |
Chi2(2) = 3.5; p = 0.18 | ||||||
Diagnostics | ||||||
Initial imaging conclusion | ||||||
Suspicious for cancer | 414 | 75.7 | 194 | 78.5 | 220 | 73.3 |
Referral for follow-up | 93 | 17.0 | 33 | 13.4 | 60 | 20.0 |
Not suspicious | 40 | 7.3 | 20 | 8.1 | 20 | 6.7 |
Chi2(2) = 4.4; p = 0.11 | ||||||
Index image | ||||||
CECT | 105 | 19.2 | 37 | 15.0 | 68 | 22.7 |
LDCT | 73 | 13.3 | 11 | 4.5 | 62 | 20.7 |
Xray | 260 | 47.5 | 149 | 60.3 | 111 | 37.0 |
None of the above | 109 | 19.9 | 50 | 20.2 | 59 | 19.7 |
Chi2(3) = 46.4; p < 0.001 | ||||||
Imaging cascade | ||||||
CECT direct (includes 7 with PET) | 87 | 15.9 | 28 | 11.3 | 59 | 19.7 |
LDCT or ULDCT | 71 | 13.0 | 9 | 3.6 | 62 | 20.7 |
Xray then CECT | 207 | 37.8 | 129 | 52.2 | 78 | 26.0 |
Xray then LDCT | 82 | 15.0 | 33 | 13.4 | 49 | 16.3 |
Other | 100 | 18.3 | 48 | 19.4 | 52 | 17.3 |
Chi2(4) = 61.9; p < 0.001 | ||||||
Clinical pathway | ||||||
Pathway | ||||||
Lung cancer referral pathway | 40 | 7.3 | 16 | 6.5 | 24 | 8.0 |
Urgent referral pathway for non-specific serious symptoms | 94 | 17.2 | 47 | 19.0 | 47 | 15.7 |
LDCT pathway | 73 | 13.3 | 11 | 4.5 | 62 | 20.7 |
Not a defined clinical pathway | 340 | 62.2 | 173 | 70.0 | 167 | 55.7 |
Chi2(3) = 35.5; p < 0.001 | ||||||
Timing of investigation and diagnosis | ||||||
Days from investigation to diagnosis | ||||||
Less than 31 | 431 | 78.8 | 205 | 83.0 | 226 | 75.3 |
31–60 | 33 | 6.0 | 12 | 4.9 | 21 | 7.0 |
61–179 | 29 | 5.3 | 9 | 3.6 | 20 | 6.7 |
≥ 180 | 53 | 9.7 | 20 | 8.1 | 33 | 11.0 |
NA | 1 | 0.2 | 1 | 0.4 | 0 | 0.0 |
Chi2(4) = 6.8; p = 0.15 | ||||||
Chi2(3) = 5.6; p = 0.14 (ex. NA) | ||||||